Antithrombin III pretreatment reduces neutrophil recruitment into the lung in a rat model of abdominal sepsis

Acta Anaesthesiologica Scandinavica

Volumn 49, Issue 2, 2005, Pages 203-208

  Koca, Uĝur ^a   Olguner, C ^a   Ozkardesler S ^a   Karci, A ^a   Coker C ^a   Tuncel, P ^a   Tasdogen A ^a   Duru, S ^a   Ulukus C ^a   Elar, Z ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Activated leukocytes; Anti inflammatory; Antithrombin; Heparin like glycosaminoglycans; Prostacyclin; Sepsis

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANTITHROMBIN III; KYBERNIN P HUMAN AT III; MYELOPEROXIDASE; PROSTACYCLIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CECUM; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; INTESTINE PERFORATION; LAPAROTOMY; LEUKOCYTE COUNT; LIPID PEROXIDATION; LUNG ALVEOLUS; LUNG CAPILLARY; LUNG INFILTRATE; LUNG INJURY; LUNG PARENCHYMA; MALE; MEDIATOR RELEASE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; STERNOTOMY; TRACHEA;

ABDOMINAL CAVITY; ANIMALS; ANTITHROMBIN III; DISEASE MODELS, ANIMAL; EPOPROSTENOL; LIPID PEROXIDATION; LUNG; LUNG DISEASES; MALE; NEUTROPHIL INFILTRATION; PEROXIDASE; RATS; RATS, WISTAR; SEPSIS; SERINE PROTEINASE INHIBITORS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 20044395421     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2004.00567.x     Document Type: Article

References (46)

1. Windsor AC, Mullen PG, Fowler AA, Sugerman HJ. Role of the neutrophil in adult respiratory distress syndrome. Br J Surg 1993; 80: 10-7.
2. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001; 184: 258-74.
3. Weiss SJ & LoBuglio AF. An oxygen-dependent mechanism of neutrophil-mediated cytotoxicity. Blood 1980; 55: 1020-4.
4. Emerson TE, Fournel MA, Leach WJ, Redens TB. Protection against disseminated intravascular coagulation and death by antithrombin III in the Escherichia coli endotoxemic rat. Circ Shock 1987; 21: 1-13.
5. Korthius RJ, Grisham MB, Granger DN. Leukocyte depletion attenuates vascular injury in postischemic skeletal muscle. Am Physiol Heart Circ Physiol 1998; 254: H823-H827.
6. Matsuda T, Rubinstein I, Robbins RA, Kayama S, Joyner WL, Rennard SI. Role of neutrophils in endotoxin-mediated microvascular injury in hamsters. J Appl Physiol 1991; 71: 307-13.
7. Lowry SF. Cytokine mediators of immunity and inflammation. Arch Surg 1993; 128: 1235-41.
8. Parillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-7.
9. McCuskey R, Urbaschek R, Urbaschek B. The microcirculation during endotoxemia. Cardiovasc Res 1996; 32: 752-63.
10. Neumann B, Zantl N, Veihelmann A, Emmanuilidis K, Pfeffer K, Heidecke CD et al. Mechanisms of acute inflammatory lung injury induced by abdominal sepsis. Int Immunol 1999; 11: 217-27.
11. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-70.
12. Clotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994; 144: 975-85.
13. Uchiba M, Okajima K, Murakima K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270: L921-L930.
14. Kaneider NC, Egger P, Duzendorfer S, Wiedermann CJ. Syndecan-4 as an antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001; 287: 42-6.
15. Ostrovsky L, Woodmann RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997; 96: 2302-10.
16. Ostrovsky L, Carvalho-Tavares J, Woodmann RC, Kubes P. Translational inhibition of thrombin-induced E-selectin expression stimulates P-selectin-dependent neutrophil recruitment. Am J Physiol Heart Circ Physiol 2000; 278: H1225-H1232.
17. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock. A review of laboratory models and a proposal. J Surg Res 1980; 29: 189-201.
18. Nardo B, Caraceni P, Pasini P, Domenicali M, Catena F, Cavallari G et al. Increased generation of reactive oxygen species in isolated rat fatty liver during post ischemic reoxygenation. Transplantation 2001; 7: 1816-20.
19. Krawisz JE, Sharon P, Stenson WF. Quantitative assay of acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 1344-50.
20. King J, Deboisblanc BP, Mason CM, Onofrio JM, Lipscomb G, Mercante DE et al. Effect of granulocyte colony-stimulating factor on acute lung injury in the rat. Am J Respir Crit Care Med 1995; 151: 302-9.
21. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock 1998; 9: 1-11.
22. Cook JA, Wise WC, Buther RR, Reines HD, Rambo W, Halushka FV. The potential role of thromboxane and prostacyclin in endotoxic and septic shock. Am J Emerg Med 1984; 2: 28-37.
23. Wang P, Zhou M, Cioffi WC, Bland KL, Ba ZF, Chaudry IH. Is prostacyclin responsible for producing the hyperdynamic response during early sepsis? Crit Care Med 2000; 28: 1534-9.
24. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998; 89: 233-41.
25. Ozden A, Tetik C, Bilgihan A, Cali N, Bostanci B, Yis O et al. Antithrombin III prevents 60 min warm intestinal ischemia reperfusion injury in rats. Res Exp Med 1999; 198: 237-46.
26. Liaudet L, Mabley JG, Soriano FG, Pacher P, Marton A, Hasko G et al. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med 2001; 164: 1213-20.
27. Beachtold F, Scott JA, Markert M, Mehta S, McCormack DG, Anglaa F et al. Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture? Shock 2001; 16: 137-42.
28. Ozdulger A, Cinel I, Koksel O, Cincel L, Unlu A, Okcu H et al. The protective effect of N-acetylcysteine on apoptotic lung injury in cecal ligation and puncture-induced sepsis model. Shock 2003; 19: 366-72.
29. Goode HF, Courley HC, Walker BE, Howdle PD, Webster NR. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit Care Med 1995; 23: 646-51.
30. Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, Giamarellou H. In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 283-7.
31. 1α in rats. Thromb Res 1995; 80: 201-8.
32. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59: 899-904.
33. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30 (Suppl. 5): S325-S331.
34. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989; 163: 1404-11.
35. Tateson JE, Moncada S, Vane JR. Effects of prostacyclin on cyclic AMP concentration in human platelets. Prostaglandins 1977; 13: 389-97.
36. Eisenhut T, Sinha B, Grottrup-Wolfers E, Semler J, Siess W, Enders S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 1993; 26: 259-64.
37. Kainoh M, Iamai R, Umetsu T, Hattori M, Nishio S. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39: 477-84.
38. Riva C, Morganroth ML, Ljungman AG, Schoeneich SO, Marks RM, Todd RF et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Resp Cell Mol Biol 1990; 3: 301-9.
39. Redens TB, Leach WJ, Bogdanoft DA, Emerson TE. Synergestic protection from lung damage by combining antithrombin III and alpha-1-proteinase inhibitor in the E.coli endotoxic sheep pulmonary dysfunction model. Circ Shock 1988; 26: 15-26.
40. Hauptman JG, Hassouna HI, Bell TG, Penner JA, Emerson TE. Efficacy of antithrombin III in endotoxin-induced disseminated intravascular coagulation. Circ Shock 1988; 25: 111-22.
41. Emerson TE. Antithrombin III replacement in animal model of acquired antithrombin III deficiency. Blood Coagul Fibrinolysis 1994; 5 (Suppl. 1): S37-S45.
42. Warren BL, Eid A, Singer P, Pillay SS, Novak I, Chalupa P et al. KyberSept Trial Study Group. High dose antithrombin III in severe sepsis: a randomized controlled study. JAMA 2001; 286: 1869-78.
43. Eisele B, Lamy M, Thijs LG, Keinecke HO, Shuster HP, Matthias FR et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with AT III in severe sepsis. Intensive Care Med 1998; 24: 663-72.
44. Esmon CT. Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 2004; 32 (Suppl. 5): S219-S222.
45. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
46. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis. Benefical effects on organ dysfunction. Shock 1997; 8: 328-34.